Intelligent Bio Solutions Inc. announced its financial results and operational highlights for the fiscal fourth quarter and full-year ended June 30, 2025. Fiscal Q4 revenue increased by 16% year-on-year and quarter-on-quarter, supported by increased demand for drug testing cartridges.
Fiscal 2025 was characterized by growth, driven by higher-margin cartridge sales, operational streamlining, and regulatory advancements supporting future U.S. market expansion beyond Forensic Use Only settings. The company's active customer base exceeds 450 accounts across 24 countries, with 18 distribution partners.
INBS remains focused on securing FDA 510(k) clearance for its opiate test system for codeine in the U.S., having advanced its regulatory strategy through increased engagement with consultants and new scientific data. The company implemented targeted measures to improve gross margins and reduce net loss, including product enhancements and manufacturing improvements.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.